Linked Life Data

8300056

Source:http://linkedlifedata.com/resource/pubmed/id/8300056

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
1994-3-10
pubmed:abstractText
Growth hormone (GH) and insulin-like growth factors (IGFs) play a central role in skeletal growth and bone remodeling. In vitro, both agents display anabolic properties, and patients with acromegaly exhibit increased bone mass. Recent in vivo studies have demonstrated profound activation of bone remodeling that lasted for months after a single 1-week dose of GH or IGF-I. Despite these positive effects, the few clinical studies conducted with GH in osteoporotic patients have shown disappointing results in terms of bone mass changes. Changes in dosing regimens and other adjuvant therapies may, however, lead to more efficient use of these agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0301-0163
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
95-8
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis.
pubmed:affiliation
Aarhus Bone and Mineral Research Group, Aarhus Amtssygehus, Denmark.
pubmed:publicationType
Journal Article, Review